The precise immunological mechanisms underlying the
beneficial clinical effects of subcutaneous immunotherapy
(SCIT) and sublingual immunotherapy (SLIT) remain a
matter of research and debate. Changes to T-cell reactivity
and induction of blocking antibodies such as IgG4 and IgA are
regarded as immunological markers of clinical tolerance [9].